Featured Clinical Trial:
Rheumatoid arthritis, osteoarthritis (product/compound: Celecoxib; Ibuprofen; Naproxen)
ClinicAid Locations: Southern California – Bellflower
Status:
Open for enrollment (accepting patients).
Please contact us and mention Trial ID NCT00346216.
Condition: Rheumatoid Arthritis, Osteoarthritis
Product Name/Compound: Celecoxib; Ibuprofen; Naproxen
Full Study Title: A Randomized, Double Blind, Parallel-Group Study Of Cardiovascular Safety In Osteoarthritis Or Rheumatoid Arthritis Patients With Or At High Risk For Cardiovascular Disease Comparing Celecoxib With Naproxen And Ibuprofen (PRECISION)
Study Summary: Assess overall benefit: risk of celecoxib when compared to two most commonly prescribe traditional (non-selective) nonsteroidal anti-inflammatory drugs (NSAIDs) in the treatment of arthritis pain. For this purpose, patients with osteoarthritis or rheumatoid arthritis with or at risk of developing cardiovascular disease will be recruited. The cardiovascular, gastrointestinal and renal safety and symptomatic benefit in each treatment group will be assessed accordingly.
Eligible Participants:
Inclusion (Eligible):
- Subjects with osteoarthritis or rheumatoid arthritis with or at risk of developing cardiovascular disease and who require and eligible for chronic, daily therapy with an NSAID to control arthritis sign and symptoms
Exclusion (Not Eligible):
- Subjects have had a recent cardiovascular event, unstable cardiovascular conditions, or any major surgery (cardiac or non-cardiac) within 3 months prior to randomization;
- Subjects with medical or laboratory abnormality that would make the subject inappropriate for entry into this trial
- Subjects require treatment with aspirin > 325 mg /day
- Subjects with known hypersensitivity to celecoxib, ibuprofen, naproxen, aspirin or esomeprazole, etc
Study Phase: Phase IV (What are Phases?)
To receive information and updates for this trial:
Please contact us and mention the Trial ID below.
Trial ID (ClinicalTrials.gov): NCT00346216
<< Back to all ClinicAid clinical trials
